GLP-1 Weight Loss Drugs Linked to Rare, Life-Threatening Brain Disorder
A recent study conducted by researchers in Israel suggests a potential link between popular GLP-1 weight loss drugs and Wernicke encephalopathy (WE), a rare but serious neurological disorder. The study, which examined 195,979 cases, identified 15 instances of WE disproportionately associated with GLP-1 medications, specifically semaglutide (sold as Ozempic, Wegovy, and Rybelsus) and tirzepatide (sold as Mounjaro and Zepbound). GLP-1 drugs work by slowing digestion, leading to reduced appetite and food intake. This can result in inadequate nutrition, including a deficiency in vitamin B1 (thiamine), which is crucial for brain cell energy production. Without sufficient thiamine, brain cells cannot function properly, potentially causing inflammation and swelling in brain regions responsible for memory and balance, leading to WE. Most patients in the study who developed WE experienced gastrointestinal issues such as weight loss, vomiting, loss of appetite, or malnutrition, all of which contribute to vitamin B1 ...